Sir Greg Winter是Bicycle Therapeutics的联合创始人。 Bicycle作为开发新型环肽药物的领军企业,其技术平台的应用包含了单价双环肽、双特异性双环肽、多特异性双环肽、多肽-药物偶联物和多肽-寡核苷酸偶联物,与抗体药物的应用范围具有完美的重叠。 Part.2 技术平台 Bicycle具有专有的噬菌体筛选平台,利用基因工程手段将外源...
Bicycle具有专有的噬菌体筛选平台,利用基因工程手段将外源基因片段插入至噬菌体特定蛋白基因中,经过表达得到重组多肽库,与特异性分子结合即可发现靶向肽。 Bicycle的分子量在1.5KDa-2KDa之间,具有良好的组织渗透率和肾脏清除率、高度亲和力和选择性的优点,较大的分子足迹可使得蛋白间的相互作用具有靶向性,结合了生物药的...
研发公司:Bicycle Therapeutics 说明书: 药品概述 BT8009是另一种针对Nectin-4的临床试验中的PDC,Nectin-4在许多癌症(包括肺癌,乳腺癌,膀胱癌和胰腺癌)中过表达。该PDC结构类似于BT5528,具有通过Val-Cit可裂 解连接子结合在一起的MMAE有效载荷。BT8009在临床试验中显示出令人鼓舞的结果,并证明在临床前模型中具有选...
Bicycle公司基于双环肽噬菌体展示技术开发了靶向Nectin-4的双环肽分子,并经过一系列的优化设计、偶联药物等,设计出一种多肽偶联药物BT8009。BT8009在多种肿瘤模型中具有有效疗效,包括患者来源的异种移植物,跨越了多种肿瘤适应症,在临床前安全性研究中耐受性良好。在几个模型中,表现出优越的或与ADC药物PADCEV类似物相...
Bicycle (BCYC)和FDA已经在讨论设计一项验证性试验,以测试BT8009对先前治疗过的转移性膀胱癌的疗效。 公告发布后,投行B. Riley将BCYC的评级从中性上调为买入,并指出“Bicycle不仅找到了一条加速的道路,而且将从一开始就直接瞄准一线市场,这是最大的潜在机会。” ...
2022 AACR会议上,Bicycle Therapeutics 公布了其基于双环肽在研疗法BT8009的最新临床试验结果。Bicycle Therapeutics 公司基于Bicycle技术开发了2款靶向Nectin-4的疗法。一种Bicycle Toxin Conjugate(BTC)—BT8009;另一种是双特异性双环肽—BT7480。图片上传中...BT8
(nM) 13 cLogP -6.74 T1/2 (plasma) >24h Solubility = 4.9 ug/ml, LogD = -0.7 Optimised Bicycle Ac C P 1Nal d C M hArg D W S T P Hyp W C + affinity + hydrophilicity + affinity, hydrophilicity BT8009; Bicycle Toxin conjugate Β-Ala Sar Sar Sar Increase affinity and improve ...
Abstract 391: Molecular-based enrichment strategy for Nectin-4 targeted Bicycle toxin conjugate BT8009Introduction: BT8009 consists of a bicyclic peptide targeting the tumor antigen Nectin-4, linked to the cytotoxin monomethyl auristatin E (MMAE) via a molecular spacer and cleavable linker. BT8009 ...
Bicycle (BCYC) — BCYC has been under pressure recently after the company provided updates on its zelenectide (BT8009) program. The company provided topline Phase I/II Duravelo-1 data of zelenectide+pembro combo in 1L mUC, timing expectations for subsequent Phase II/III Duravelo-2 read...
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies. Background: BT7480 is a novel, first-in-class, Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist (Bicycle TICA) that co-ligates cluster...